FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
23/09/2026 22:42
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy Sept 23 (Reuters) - A panel of outside experts advising the US FDA backed the safety of Grail's GRAL.O blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.
While all the 10 panel members backed Galleri's safety, support for its effectiveness was narrower, with a 6-4 vote in favor.
(Reporting by Padmanabhan Ananthan and Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM